3-Ethyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate/Nitrendipine/1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester/Ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate/Bylotensin/ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate/Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(meta-nitrophenyl)-3,5-pyridinedicarboxylate/3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester/Deiten
488.9±45.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:39562-70-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Microradioautographic study of [3H]-benidipine hydrochloride (KW-3049, CAS 91599-74-5) and nitrendipine (CAS 39562-70-4) localization was performed in the supramesenteric arteries of the spontaneously hypertensive rats (SHR) at 10 and 30 min after intravenous administration or in vitro incubation. The distribution of silver grains was observed by light and electron microscopy and the number of grains was counted in the tunicae intima, media and adventitia of the arteries. Areas of the correlated part of the artery were measured and the grain count per area was calculated. The grain count of [3H]-benidipine hydrochloride showed almost uniform distribution in the tunicae intima and media, which was compared at 10 and 30 min after the administration both in the in vivo and in the in vitro studies. The grain density of [3H]-nitrendipine to the tunicae intima and media increased time-dependently. Electron microscopic observation revealed that the fine distribution of [3H]-benidipine hydrochloride was mainly localized on the plasma membrane and on the cytoplasm of the cellular components of the mesenteric artery. The result suggested that the distribution of [3H]-benidipine hydrochloride was related to its pharmacologically active site, i.e. plasma membrane of the tunica intima and the smooth muscle cells of the tunica media.
Radioautographic Study of Benidipine Hydrochloride. Localization in the Mesenteric Artery of Spontaneously Hypertensive Rat
K Suzuki 1, T Imada, F Gao, H Ma, T Nagata
Many large multicenter clinical drug trials are outcome trials with several thousand patients, therefore also called megatrials, numerous of which encompassing the cardiovascular field. Usually designed to test and compare the efficacy of a specific therapy with the major aim being improved outcome at hard end-points, specifically morbidity and mortality, they are representative of typical intervention trials. Considering also the risk of failure, examples of large multicenter therapy trials are examined as to their value to the patients, the society, the health care providers, and–finally–also the manufacturers of the respective drugs. The ‘Syst-Eur Trial’ (Systolic Hypertension in Europe) representing a very recent intervention trial to treat isolated high systolic blood pressure in elderly patients with treatment based on a calcium channel blocker, nitrendipine (CAS 39562-70-4, Bayotensin, Baypress), serves to indicate that besides the major end-point results, here total stroke rate, a number of important additional efficacy and safety results may be obtained with large trials, such as in this case favourable data on total mortality, myocardial infarctions, cancer, bleeding.
On the Value of Large Multicenter Drug Intervention Trials
P Dernol 1, G E Hubner, T R Weihrauch